<DOC>
	<DOC>NCT01707394</DOC>
	<brief_summary>CV185118 is a single dose Apixaban PK/PD study in pediatric subjects. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric subjects at risk for thrombosis</brief_summary>
	<brief_title>Study to Evaluate a Single Dose of Apixaban in Pediatric Subjects at Risk for a Thrombotic Disorder</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Subjects with any stable disease that are at risk for a venous or arterial thrombotic disorder Neonates (≥ 34 weeks gestation at birth or ≥ 37 weeks post conceptual age) to &lt; 18 years of age Subjects with any functional CVAD (Central Venous Access Device) in the upper or lower venous system Current or recent (within 3 months of study drug administration) gastrointestinal disease or gastrointestinal surgery that, in the opinion of the investigator and the BMS Medical Monitor, could impact the absorption of the study drug Active bleeding or high risk of bleeding Inability to tolerate oral medication or administration of oral medication via an enteral tube (nasogastric tube [NG tube] or gastronomy tube [Gtube])</criteria>
	<gender>All</gender>
	<minimum_age>37 Weeks</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>